Pfizer and Avon Announce Metastatic Breast Cancer Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer and Avon Announce Metastatic Breast Cancer Program


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

To help increase support for people living with metastatic breast cancer and their caregivers, Pfizer and the Avon Foundation for Women have partnered to establish the Avon-Pfizer Metastatic Breast Cancer Grants Program.The partnership will award up to $1 million in grants to advocacy, academic, and other not-for-profit organizations who serve the metastatic breast cancer community. The program will support initiatives to provide information and services that help people with metastatic breast cancer navigate the medical and emotional challenges associated with their disease.

A survey commissioned by Pfizer found that more than 60% of respondents say they know little to nothing about metastatic breast cancer, which occurs when cancer spreads beyond the breast to other parts of the body, including the bones, lungs, liver and brain. The survey was the first to examine the general public’s understanding of metastatic breast cancer, which affects up to 250,000 women and men in the US. The survey results reveal a range of misperceptions about the causes, treatments, and outcomes related to metastatic breast cancer.

The Metastatic Breast Cancer Grants Program is designed to address many of the misperceptions found in the survey including 72% of respondents believe that breast cancer in the advanced stages is curable if diagnosed early and 50% of respondents believe that people with breast cancer experience disease progression because they did not take the right medicines or preventative measures.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here